Pennsylvania has secured over $1 billion in private-sector investment from global health care company Johnson & Johnson to build a next generation cell therapy manufacturing facility in Montgomery County. Supported by a $41.5 million state investment, this expansion project will create more than 500 new jobs over the next twelve years and continue growing Pennsylvania’s robust life sciences industry. The project also helps retain 5,885 full-time jobs statewide.
Johnson & Johnson is constructing this state-of-the-art cell therapy manufacturing facility in Lower Gwynedd Township, Montgomery County. The facility will be operated by its subsidiary Janssen Biotech and will directly support the production of medicines for cancer, immune-mediated, and neurological diseases.
“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” said Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson. “By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families.”
Johnson & Johnson received a funding proposal from DCED for up to $12 million in tax credits through the Qualified Manufacturing Innovation and Reinvestment Deduction (QMIRD) program, up to $2 million in tax credits through the Manufacturing Tax Credit (MTC) program, a $15 million grant through the PA SITES (Pennsylvania Strategic Investments to Enhance Sites) program, and a $10 million Pennsylvania First grant.
The state has also committed to providing a Redevelopment Assistance Capital Program (RACP) award of up to $2.5 million to a local community college and/or technical school to help create a workforce development training program that would serve as a talent pipeline for the company in Montgomery County.
“We value Johnson & Johnson’s long-time partnership here in Pennsylvania, and its decision to reinvest in Montgomery County is another huge win for the Commonwealth – further expanding our life science ecosystem, while also producing life-saving medications for people undergoing cancer treatment, ” said Secretary Siger. “This announcement also sends a clear message that Pennsylvania is competing — and winning — when it comes to attracting world-class life sciences companies, growing high-quality jobs, and driving long-term economic growth across the Commonwealth. We will continue to support projects like this by making investments that keep our economic momentum going and spur our innovation economy.”
Johnson & Johnson, a global health care company, is focused on innovative medicine and medtech solutions, guided by its purpose to profoundly impact health for humanity. The company generates an estimated $10 billion in annual economic impact across Pennsylvania. With ten facilities spanning more than 2 million square feet for manufacturing, research, distribution, and office operations, the company holds one of the largest statewide footprints in the health care industry.
